热门资讯> 正文

Terns Pharmaceuticals提议4亿美元的股权发行

2025-12-09 19:37

Terns Pharmaceuticals, Inc.(TERN) 0

Terns Pharmaceuticals (TERN) has launched a proposed $400M public offering of common stock and pre-funded warrants.
The company also plans to give underwriters a 30-day option to buy up to an additional $60M in shares. Terns plans to use the net proceeds from the proposed offering to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701, and for working capital and general corporate purposes.
TERN -4.28% premarket at $38.51.

More on Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript
Terns Pharmaceuticals: GLP-1 Obesity Drug Cut Warrants Downgrade To 'Hold' Rating
Terns Pharmaceuticals: Valued As If It Can't Win
Terns Pharmaceuticals GAAP EPS of -$0.27
Terns falls as phase 2 data on oral GLP-1 obesity asset disappoints

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。